Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Active not recruiting 2Recruiting 1

Sponsor Class

NIH 3

Study Type

Interventional 3

Sponsor

Cancer Type

Sarcoma 3

Conditions

Prostatic Neoplasms 86Lung Neoplasms 64Carcinoma, Non-Small-Cell Lung 50Neoplasm Metastasis 48Breast Neoplasms 48Glioma 41Glioblastoma 38Pancreatic Neoplasms 35Multiple Myeloma 35Brain Neoplasms 34Carcinoma, Renal Cell 33Lymphoma, Large B-Cell, Diffuse 29Melanoma 28Urinary Bladder Neoplasms 27Colorectal Neoplasms 27Squamous Cell Carcinoma of Head and Neck 25Ovarian Neoplasms 24Triple Negative Breast Neoplasms 21Oropharyngeal Neoplasms 21Carcinoma, Hepatocellular 21Lymphoma 20Mouth Neoplasms 18Lymphoma, Follicular 18Sarcoma 17Fallopian Tube Neoplasms 16Carcinoma, Transitional Cell 16Carcinoma 16Laryngeal Neoplasms 15Astrocytoma 15Lymphoma, Mantle-Cell 14

Interventions

Doxorubicin 5pembrolizumab 4Specimen Handling 4Radiotherapy 4Radiation 4Nivolumab 4Magnetic Resonance Spectroscopy 3Ipilimumab 3CTLA-4 Antigen 3Biopsy 3cabozantinib 2Ifosfamide 2tremelimumab 1talimogene laherparepvec 1regorafenib 1peposertib 1pazopanib 1olaratumab 1liposomal doxorubicin 1futibatinib 1fludarabine 1eribulin 1durvalumab 1avelumab 1aldesleukin 1X-Rays 1Trabectedin 1Standard of Care 1Quality of Life 1Injections 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Histiocytoma, Malignant Fibrous × Magnetic Resonance Spectroscopy × 1 year × Clear all
NCT05711615 2026-05-15

Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma

National Cancer Institute (NCI)

Phase 1 Recruiting
30 enrolled
Sarcoma

Leiomyosarcoma, Liposarcoma, Sarcoma, Sarcoma, Synovial, Dermatofibrosarcoma, Histiocytoma, Malignant Fibrous

NCT02923778 2026-05-13

Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by Surgery

National Cancer Institute (NCI)

Phase 2 Active not recruiting
40 enrolled
Sarcoma

Leiomyosarcoma, Liposarcoma, Sarcoma, Histiocytoma, Malignant Fibrous

NCT05836571 2026-04-21

Testing Ipilimumab and Nivolumab Combination With or Without Cabozantinib in People >= 18 Years Old With Advanced Soft Tissue Sarcoma

National Cancer Institute (NCI)

Phase 2 Active not recruiting
66 enrolled
Sarcoma

Sarcoma, Histiocytoma, Malignant Fibrous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡